Formulation and evaluation of Chewable tablets Containing Dexibuprofen as an Antipyretic Drug

Antipyretic medications are frequently required for fever, a natural physiological reaction to infection or inflammation, to reduce symptoms and enhance patient comfort. The active enantiomer of ibuprofen, dexibuprofen, offers a more appealing substitute because of its improved pharmacokinetic characteristics, which include a longer half-life and less gastrointestinal side effects. To overcome the drawbacks of traditional dose forms and enhance patient compliance, particularly in the case of juvenile and geriatric populations, this research study describes the development and assessment of a unique chewable tablet containing dexibuprofen as an antipyretic medication. To maximize medication distribution and improve palatability, dexibuprofen was carefully blended with excipients and flavoring ingredients during the formulation process. The prepared chewable tablets were thoroughly examined for their physical attributes, homogeneity of drug content, disintegration time, dissolution profile, and palatability. According to the results, the chewable tablets met or exceeded pharmacopeial requirements for positive qualities such as consistent drug content, quick disintegration, complete dissolve, and acceptable palatability. The study's conclusions imply that the chewable tablet that was created offers a viable way to manage fevers, addressing issues with conventional dose forms while offering quick and efficient relief. Furthermore, the chewable formulation's appeal and convenience may help to boost treatment results and patient adherence, which would increase overall therapeutic efficacy in fever management circumstances.